Oleanz Forte

Olanzapine is an atypical antipsychotic medication of the thienobenzodiazepine class primarily used to treat schizophrenia and bipolar I disorder, including manic or mixed episodes.[1][2] Developed by Eli Lilly and Company and marketed under the brand name Zyprexa, it received FDA approval on September 30, 1996, for schizophrenia in adults and later for adolescents aged 13 and older, as well as bipolar disorder.[3][4] Olanzapine exerts its therapeutic effects mainly through antagonism of dopamine D2 and serotonin 5-HT2A receptors in the mesolimbic pathway, though its multi-receptor binding profile also contributes to efficacy against negative symptoms and mood stabilization.[1] It is noted for high efficacy in reducing psychotic symptoms but is associated with prominent metabolic side effects, including substantial weight gain, dyslipidemia, and increased risk of diabetes, which distinguish it among second-generation antipsychotics for having one of the most adverse cardiometabolic profiles.30416-X/fulltext)[5] These risks, along with manufacturer settlements exceeding $1 billion for off-label promotion and minimizing diabetes warnings, have marked significant controversies in its clinical use and regulatory history.[6]